An interventional study of Intervention 1 Group and Intervention 2 Group in Diabetes Mellitus, Respiratory Failure and Pneumonia, sponsored by Nilgün Erdoğan. Recruiting at 1 site in Turkey. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by Nilgün Erdoğan · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Diabetes Mellitus with a site in Turkey — 37 open to participants now, 44 under way, 1 of them phase 3. Diabetes Mellitus · Turkey.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, this one is the 111th largest by planned enrollment of the 147 interventional ones that give a count, is one of 25 that started in 2024, is one of 92 with no phase, reaches primary completion later than 5 of the 43 other live ones, and was the 162nd registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →37 of the 246 studies in Diabetes Mellitus with a site in Turkey are open now. Recruiting first, the newest first:
Aylin DEMİR · Sites in Turkey
Ages 35–65
Bilecik Seyh Edebali Universitesi · Sites in Turkey
Ages 18–65
Abant Izzet Baysal University · Sites in Turkey
Ages 65+ · Healthy volunteers
Kırıkkale University · Sites in Turkey
Ages 30–75 · Men only · Healthy volunteers
Ataturk University · Sites in Turkey
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 38 · Phase 4 15
First in 2002; this study’s year is marked. 25 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 90 across the 147 interventional studies, 120 across the 97 observational. Of the 192 that completed or were terminated, 45 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 246 have an industry lead sponsor. The 10 most frequent:
Nilgün Erdoğan is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Nilgün Erdoğan has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
8 of the studies in Diabetes Mellitus with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491185Ege UniversityEffect of Glycemic Control on Intraoperative NIRS and Postoperative Recovery in Diabetic Patients | 2026-11 |
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07734428Istanbul Bilgi UniversityInflammation and Diabetes: Evaluating Antioxidant Levels | 2026-12-30 |
| NCT07329985Bilecik Seyh Edebali UniversitesiFEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES | 2027-01-15 |
| NCT07905274Bandırma Onyedi Eylül UniversitySarcopenia Risk in Obese T2DM Patients | 2027-03-20 |
Add all 8 to your calendar (.ics) → With an account.
Among the 246 studies in Diabetes Mellitus with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sleep disturbance is one of the most common complaints of patients admitted to ICU. Insufficient sleep in intensive care units may be associated with environmental reasons such as excessive light at night, loud warning sounds and mechanical ventilation alarms, as well as non-environmental factors, including the situation at the time of admission. Sleep assessment is subjective in nature, so it is difficult to perform in the ICU. Since communication with the patient is prevented, clear information about perceived rest and disturbing factors cannot be provided. For this reason, night rest is an issue that is often forgotten and ignored. This study applied a mixture of lavender, medicinal chamomile and neroli oil (in 20 ml of sweet almond oil; lavender oil 2 drops, medicinal chamomile 4 drops, neroli oil 6 drops) to patients who were monitored in intensive care on high-flow and oxygen, once a day for three days. This study will be conducted to determine the effect of aromatherapy massage applied for a total of 30 minutes on sleep quality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In this group, application is made with chamomile, lavender and neroli oil.
Other: Intervention 1 Group
In this group, application is made with lavender oil.
Other: Intervention 2 Group
In this group, application is made only with almond oil.
Other: Placebo Control Group
20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.
It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
Patient Introduction Form
In the "Patient Introduction Form" prepared by the researcher based on the literature in order to obtain information about the characteristics of the patients who will constitute the sample, the patients' medical diagnosis, age, gender, chronic diseases, length of stay in intensive care, use of analgesic, sedative and hypnotic drugs used, normal sleep hours at night were included. There are questions about (sleep duration, daytime sleep, sleep hours, sleep aids used, etc.).
Time frame: 1 year
Patient Follow-up Form
The patient follow-up form was created by the researcher and will include the visual comparison sleep scale follow-up results, the effects of the application (whether side effects develop, its effect on the application area, the patient's condition, etc.) and the dosage of the hypnotic and sedative drugs the patient took in the intensive care unit during the study. The sleep score results of the patients will be recorded on the patient follow-up form by the nurses who collected the data of the study the morning after the application (08), and the effects of the application will also be recorded by the researcher.
Time frame: 1 year
Visual Comparison Sleep Scale
It was first developed by Snyder-Halpern and Verran (1988) in 1987 to evaluate the sleep quality of sick and healthy individuals. The scale consists of 15 questions categorized under three subscales: 'discomfort' (interruptions and delays in sleep), 'effectiveness' (how good sleep rejuvenates the individual) and 'completion' (napping). Disturbance questions include: 1) waking in the middle of sleep, 2) waking after sleep onset, 3) movement during sleep, 4) firmness of sleep, 5) quality of discomfort, 6) sleep latency, and 7) quality of latency. Efficacy questions include: 1) recovery after awakening, 2) subjective sleep quality, 3) sleep adequacy assessment, 4) total sleep time, and 5) total sleep time, calculated by adding total sleep time and waking after sleep onset. Each question is scored using a 100 mm visual analogue scale. For the 'disruption' and 'completion' subscales, higher scores indicate sleep disturbance and lower scores indicate better sleep.
Time frame: 1 year
Started Jan 2024 (actual). Primary completion is estimated for Dec 2024, 11 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nilgün Erdoğan